Casi Pharmaceuticals Announces Exit Of Juventas Investment To Strengthen Balance Sheet
Round Type
Venture
RockvilleManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products ("CASI"), today announced that CASI Biopharmaceuticals (Wuxi) Co., Ltd, a subsidiary of CASI Pharmaceuticals, Inc. ("CASI Wuxi"), entered into an Equity Transfer Agreement with Shenzhen Jiadao Gongcheng Equity Investment Fund, LLP ("Jiadao Gongcheng"), pursuant to which CASI Wuxi agreed to transfer its equity interest in Juventas Biotechnology (Tianjin) Co., Ltd.("Juventas") amounting to 12.0098% total Juventas equity to Jiadao Gongcheng for RMB 240.87 million (equivalent to USD 34.03 million)
Quick answer
CASI Pharmaceuticals raised an undisclosed amount in a funding round, dated September 23, 2022. CASI Pharmaceuticals is based in Rockville, Maryland, United States.
- How much did CASI Pharmaceuticals raise?
- CASI Pharmaceuticals raised an undisclosed amount in a funding round on September 23, 2022.
- What does CASI Pharmaceuticals do?
- CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world.
- Where is CASI Pharmaceuticals based and how big is it?
- CASI Pharmaceuticals is based in Rockville, Maryland, United States. Fundz records about 45 employees.
- Who are the decision-makers at CASI Pharmaceuticals?
- Fundz holds 1 contact at CASI Pharmaceuticals, including the Senior Vice President. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as CASI Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.
- MBX Biosciences, Inc. raised $47M on November 7, 2022.
- NRx Pharmaceuticals raised $11M (Debt Financing) on November 7, 2022.
- SpringWorks raised $225M (Post-IPO Equity) on September 7, 2022.
- Abivax raised $49M (Funding Round) on September 2, 2022.
- LumaBridge raised an undisclosed amount (Private Equity) on August 23, 2022.
- Biofrontera raised $3.7M (Seed) on October 25, 2022.
Who to call at CASI Pharmaceuticals, and when
A new round usually means CASI Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day CASI Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at CASI Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at CASI Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment CASI Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
CASI Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.